Quantcast

Industry news that matters to you.  Learn more

GenomeDx Announces Research Collaboration with Astellas to Identify Genomic Drivers of Patient Response to XTANDI (enzalutamide) Capsules

GenomeDx Biosciences recently announced that it has entered into a research collaboration with Astellas, a leading global pharmaceutical company, to apply genomic tumor profiling using GenomeDx’s Decipher® Classifier and Decipher GRID® as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI® (enzalutamide).

SeraCare Launches New Quantitative Reference Materials for NGS-Based Tumor Profiling Assays

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today that the company’s precision medicine business unit has launched its second product in a growing line of reference materials for next-generation sequencing (NGS)-based tumor profiling assays. The SeraseqTM Solid Tumor Mutation Mix-I (AF1-10) contains the same mixture of mutations in key oncogenes and tumor suppressor genes as in the previously launched AF20 mix, but is offered at five additional allele frequencies.

GATC Biotech Signs a Sales and Marketing Agreement for Products and Services With Molecular Health

GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, recently announced that it has signed a commercial agreement with Molecular Health. Under this agreement, GATC Biotech will make TreatmentMAP available to patients worldwide. The initial plans of the commercial collaboration are to market and support Molecular Health’s state-of-the-art system for tumour profiling.

Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer

Caris Life Sciences® today announced the presentation of study data in small cell cervical cancer (SCCC) that shows multiplatform tumor profiling using Caris Molecular Intelligence®, the company’s panomic, comprehensive tumor profiling service, identified high expressions of certain gene mutations which may explain sensitivities and resistance to common drug therapies. Researchers found that identification of certain biomarkers may guide treatment strategies in rare, aggressive and difficult to treat gynecological cancers. The data was presented during Poster Session B on Sunday, March 29, at the Society of Gynecologic Oncology (SGO) annual meeting on Women’s Cancers in Chicago, Ill.

Caris Life Sciences’ Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies

Caris Life Sciences® today announced the presentation of important study data showing the presence of PD-1 and PD-L1 expressing cells in 1,599 gynecologic cancer samples. Using Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, researchers identified expression of programmed cell death protein-1 (PD-1) in all gynecologic cancers independent of histology while its ligand (PD-L1) expression was variable across malignancies and histologies. This data, along with two separate studies utilizing Caris Molecular Intelligence in the identification of druggable biomarkers in cervical cancers, were presented today during Poster Session B, at the Society of Gynecologic Oncology 2015 Annual Meeting on Women’s Cancers in Chicago, Ill.